Uncategorized

BioInvent International AB and Transgene announce positive Phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors.

Biocept, Inc. announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share and an accompanying warrant to purchase two shares of common stock.

Transgene and BioInvent International AB announce positive Phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces the results of resolutions presented at its Combined General Meeting, held on May 24, 2023, and made them available on the dedicated section of its website.

Biophytis SA announces that it presented the positive results of the phase 2-3 COVA study with Sarconeos in severe COVID-19 at the American Thoracic Society International Conference that was held in Washington DC between the 19th and 24th of May 2023.

As federal aid expires, lower-income Americans — who saw the largest recent gains in uninsurance trends — will likely be affected the most, according to experts.

Can Carl Icahn bend DNA-sequencing firm Illumina to his will? Shareholders will vote Thursday on removing Illumina’s CEO and chairman from the board and replacing them with nominees from the activist investor..

Bright Health, which recently said it’s looking to exit the insurance business, purchased telehealth company Zipnosis in 2021.

The notice of proposed rulemaking recommends that the CMS and states get a drug price verification survey tool to verify prices and negotiate for expensive drugs under Medicaid.

Wave will discontinue development of WVE-004 in C9-associated ALS and frontotemporal dementia after the therapy failed to show any clinical benefit in a mid-stage trial.